144 related articles for article (PubMed ID: 34789668)
1. Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis.
Jaudszus A; Pfeifer E; Lorenz M; Beiersdorf N; Hipler UC; Zagoya C; Mainz JG
J Pediatr Gastroenterol Nutr; 2022 Mar; 74(3):355-360. PubMed ID: 34789668
[TBL] [Abstract][Full Text] [Related]
2. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
Mainz JG; Lester K; Elnazir B; Williamson M; McKone E; Cox D; Linnane B; Zagoya C; Duckstein F; Barucha A; Davies JC; McNally P;
J Cyst Fibros; 2024 May; 23(3):474-480. PubMed ID: 37806792
[TBL] [Abstract][Full Text] [Related]
3. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Mainz JG; Zagoya C; Polte L; Naehrlich L; Sasse L; Eickmeier O; Smaczny C; Barucha A; Bechinger L; Duckstein F; Kurzidim L; Eschenhagen P; Caley L; Peckham D; Schwarz C
Front Pharmacol; 2022; 13():877118. PubMed ID: 35721187
[No Abstract] [Full Text] [Related]
4. Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).
Jaudszus A; Zeman E; Jans T; Pfeifer E; Tabori H; Arnold C; Michl RK; Lorenz M; Beiersdorf N; Mainz JG
Patient; 2019 Aug; 12(4):419-428. PubMed ID: 30887269
[TBL] [Abstract][Full Text] [Related]
5. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?
Pang T; Leach ST; Katz T; Jaffe A; Day AS; Ooi CY
J Gastroenterol Hepatol; 2015 May; 30(5):866-71. PubMed ID: 25376228
[TBL] [Abstract][Full Text] [Related]
6. Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.
Caley LR; Zagoya C; Duckstein F; White H; Shimmin D; Jones AM; Barrett J; Whitehouse JL; Floto RA; Mainz JG; Peckham DG
J Cyst Fibros; 2023 Mar; 22(2):275-281. PubMed ID: 36710099
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Mainz JG; Barucha A; Huang P; Bechinger L; Duckstein F; Polte L; Sadrieh P; Nährlich L; Eickmeier O; Van Dullemen S; Eschenhagen P; Schwarz C; Lüth S; Zagoya C; Graepler-Mainka U
Front Pharmacol; 2023; 14():1167407. PubMed ID: 38026920
[No Abstract] [Full Text] [Related]
8. Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients.
Tabori H; Jaudszus A; Arnold C; Mentzel HJ; Lorenz M; Michl RK; Lehmann T; Renz DM; Mainz JG
Sci Rep; 2017 Dec; 7(1):17465. PubMed ID: 29234058
[TBL] [Abstract][Full Text] [Related]
9. Fecal Calprotectin in Cystic Fibrosis and Its Relation to Disease Parameters: A Longitudinal Analysis for 12 Years.
Ellemunter H; Engelhardt A; Schüller K; Steinkamp G
J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):438-442. PubMed ID: 28207476
[TBL] [Abstract][Full Text] [Related]
10. Calprotectin in cystic fibrosis.
Rumman N; Sultan M; El-Chammas K; Goh V; Salzman N; Quintero D; Werlin S
BMC Pediatr; 2014 May; 14():133. PubMed ID: 24885444
[TBL] [Abstract][Full Text] [Related]
11. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis.
Boon M; Calvo-Lerma J; Claes I; Havermans T; Asseiceira I; Bulfamante A; Garriga M; Masip E; van Schijndel BAM; Fornes V; Barreto C; Colombo C; Crespo P; Vicente S; Janssens H; Hulst J; Witters P; Nobili R; Pereira L; Ruperto M; Van der Wiel E; Mainz JG; De Boeck K; Ribes-Koninckx C
J Cyst Fibros; 2020 Jul; 19(4):562-568. PubMed ID: 32335023
[TBL] [Abstract][Full Text] [Related]
12. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis.
Lisowska A; Madry E; Pogorzelski A; Szydłowski J; Radzikowski A; Walkowiak J
Scand J Clin Lab Invest; 2010 Sep; 70(5):322-6. PubMed ID: 20560844
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children.
Garg M; Leach ST; Coffey MJ; Katz T; Strachan R; Pang T; Needham B; Lui K; Ali F; Day AS; Appleton L; Moeeni V; Jaffe A; Ooi CY
J Cyst Fibros; 2017 Sep; 16(5):631-636. PubMed ID: 28416415
[TBL] [Abstract][Full Text] [Related]
14. Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?
Ooi CY; Pang T; Leach ST; Katz T; Day AS; Jaffe A
Dig Dis Sci; 2015 Oct; 60(10):2946-52. PubMed ID: 26271615
[TBL] [Abstract][Full Text] [Related]
15. Systematic review on fecal calprotectin in cystic fibrosis.
Lazzarotto ES; Vasco JFM; Führ F; Riedi CA; Filho NAR
J Pediatr (Rio J); 2023; 99(1):4-10. PubMed ID: 35523321
[TBL] [Abstract][Full Text] [Related]
16. Severe disease in Cystic Fibrosis and fecal calprotectin levels.
Parisi GF; Papale M; Rotolo N; Aloisio D; Tardino L; Scuderi MG; Di Benedetto V; Nenna R; Midulla F; Leonardi S
Immunobiology; 2017 Mar; 222(3):582-586. PubMed ID: 28012584
[TBL] [Abstract][Full Text] [Related]
17. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old.
Garg M; Leach ST; Pang T; Needham B; Coffey MJ; Katz T; Strachan R; Widger J; Field P; Belessis Y; Chuang S; Day AS; Jaffe A; Ooi CY
J Cyst Fibros; 2018 Jan; 17(1):109-113. PubMed ID: 28754328
[TBL] [Abstract][Full Text] [Related]
18. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis.
Fallahi G; Motamed F; Yousefi A; Shafieyoun A; Najafi M; Khodadad A; Farhmand F; Ahmadvand A; Rezaei N
Turk J Pediatr; 2013; 55(5):475-8. PubMed ID: 24382526
[TBL] [Abstract][Full Text] [Related]
19. Intestinal inflammation and impact on growth in children with cystic fibrosis.
Dhaliwal J; Leach S; Katz T; Nahidi L; Pang T; Lee JM; Strachan R; Day AS; Jaffe A; Ooi CY
J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):521-6. PubMed ID: 25539196
[TBL] [Abstract][Full Text] [Related]
20. Decreased Fecal Calprotectin Levels in Cystic Fibrosis Patients After Antibiotic Treatment for Respiratory Exacerbation.
Schnapp Z; Hartman C; Livnat G; Shteinberg M; Elenberg Y
J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):282-284. PubMed ID: 30640865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
